These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34478124)

  • 41. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.
    Dörner T; van Vollenhoven RF; Doria A; Jia B; Ross Terres JA; Silk ME; de Bono S; Fischer P; Wallace DJ
    Arthritis Res Ther; 2022 May; 24(1):112. PubMed ID: 35578304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
    Wallace DJ; Strand V; Merrill JT; Popa S; Spindler AJ; Eimon A; Petri M; Smolen JS; Wajdula J; Christensen J; Li C; Diehl A; Vincent MS; Beebe J; Healey P; Sridharan S
    Ann Rheum Dis; 2017 Mar; 76(3):534-542. PubMed ID: 27672124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis.
    Busch H; Wan GJ; Niewoehner J; Houston P; Su Y; Clinton C; Panaccio MP
    Drugs Context; 2022; 11():. PubMed ID: 35382109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
    Kaplan J; Miller T; Baker M; Due B; Zhao E
    Front Neurol; 2020; 11():598496. PubMed ID: 33414758
    [No Abstract]   [Full Text] [Related]  

  • 46. Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
    van Vollenhoven RF; Hahn BH; Tsokos GC; Lipsky P; Fei K; Gordon RM; Gregan I; Lo KH; Chevrier M; Rose S
    Arthritis Rheumatol; 2020 May; 72(5):761-768. PubMed ID: 31769212
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease.
    Toyos M; Toyos R; Jodoin B; Bunch R
    Ophthalmol Ther; 2022 Jun; 11(3):1231-1240. PubMed ID: 35460497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE; Buyon JP; Kim M; Belmont HM; Mackay M; Diamond B; Marder G; Rosenthal P; Haines K; Ilie V; Abramson SB
    Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.
    Zimmer R; Scherbarth HR; Rillo OL; Gomez-Reino JJ; Muller S
    Ann Rheum Dis; 2013 Nov; 72(11):1830-5. PubMed ID: 23172751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
    Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.
    Merrill JT; Wallace DJ; Wax S; Kao A; Fraser PA; Chang P; Isenberg D;
    Arthritis Rheumatol; 2018 Feb; 70(2):266-276. PubMed ID: 29073347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
    Humrich JY; Cacoub P; Rosenzwajg M; Pitoiset F; Pham HP; Guidoux J; Leroux D; Vazquez T; Riemekasten G; Smolen JS; Tsokos G; Klatzmann D
    Ann Rheum Dis; 2022 Dec; 81(12):1685-1694. PubMed ID: 35973803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
    Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis.
    Ho-Mahler N; Turner B; Eaddy M; Hanke ML; Nelson WW
    Open Access Rheumatol; 2020; 12():21-28. PubMed ID: 32110122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.
    He J; Zhang R; Shao M; Zhao X; Miao M; Chen J; Liu J; Zhang X; Zhang X; Jin Y; Wang Y; Zhang S; Zhu L; Jacob A; Jia R; You X; Li X; Li C; Zhou Y; Yang Y; Ye H; Liu Y; Su Y; Shen N; Alexander J; Guo J; Ambrus J; Lin X; Yu D; Sun X; Li Z
    Ann Rheum Dis; 2020 Jan; 79(1):141-149. PubMed ID: 31537547
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lima GL; Paupitz J; Aikawa NE; Takayama L; Bonfa E; Pereira RM
    Arthritis Care Res (Hoboken); 2016 Jan; 68(1):91-8. PubMed ID: 25988278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

  • 58. Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.
    van Vollenhoven RF; Stohl W; Furie RA; Fox NL; Groark JG; Bass D; Kurtinecz M; Pobiner BF; Eastman WJ; Gonzalez-Rivera T; Gordon D
    Lupus Sci Med; 2018; 5(1):e000288. PubMed ID: 30588323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.
    Závada J; Uher M; Svobodová R; Olejárová M; Hušáková M; Ciferská H; Hulejová H; Tomčík M; Šenolt L; Vencovský J
    Arthritis Res Ther; 2015 Nov; 17():341. PubMed ID: 26608564
    [TBL] [Abstract][Full Text] [Related]  

  • 60. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.
    Yee CS; Farewell V; Isenberg DA; Rahman A; Teh LS; Griffiths B; Bruce IN; Ahmad Y; Prabu A; Akil M; McHugh N; D'Cruz D; Khamashta MA; Maddison P; Gordon C
    Arthritis Rheum; 2007 Dec; 56(12):4113-9. PubMed ID: 18050213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.